Advaxis, Inc. Announces Filing of Proxy Statement Supplement and New Annual Meeting Date
5/23/2013 7:50:13 AM
More...
|
Advaxis, Inc. Announces Promotion of Dr. Robert Petit and Daniel J. O’Connor
5/6/2013 6:46:33 AM
More...
|
Advaxis, Inc. and FusionVax Sign a Memorandum of Understanding for the License of Advaxis' ADXS-HPV in Asia
4/22/2013 12:56:04 PM
More...
|
Advaxis, Inc. to Present at the Biotechnology Industry Organization (BIO) International Convention
4/18/2013 7:15:08 AM
More...
|
Advaxis, Inc. to Report 12-Month Survival From Its Phase 2 Study of ADXS-HPV in Women With Recurrent/Refractory Cervical Cancer
4/17/2013 11:21:42 AM
More...
|
University of Pennsylvania Researchers Receive Penn One Health Award for Research Initiatives in Canine Osteosarcoma With Advaxis, Inc.'s ADXS-cHER2 Immunotherapy
3/11/2013 10:52:37 AM
More...
|
Advaxis, Inc. Announces Phase 1/2 Trial of ADXS-HPV in Anal Cancer Conducted by Brown University Oncology Group
2/19/2013 9:32:50 AM
More...
|
Advaxis, Inc. to Present at the 15th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference
2/7/2013 6:28:30 AM
More...
|
Advaxis, Inc. Receives Preliminary Approval for Sale of Losses From State of NJ Economic Development Authority
12/13/2012 10:09:09 AM
More...
|
Advaxis, Inc. to Present at NYC MedTech Program
12/3/2012 10:49:59 AM
More...
|
|